| Ticker | Volume | Price | Price Delta |
|---|---|---|---|
| DJIA | 14,891.30 | -220.90 | -1.46% |
| S&P 500 | 1,600.54 | -28.39 | -1.74% |
| Nasdaq | 3,390.02 | -53.18 | -1.54% |
| Ticker | Volume | Price | Price Delta |
|---|---|---|---|
| STOXX 50 | 2,589.52 | -94.46 | -3.52% |
| FTSE 100 | 6,154.27 | -194.55 | -3.06% |
| DAX | 7,934.83 | -262.25 | -3.20% |
| Ticker | Volume | Price | Price Delta |
|---|---|---|---|
| Nikkei | 13,014.60 | -230.64 | -1.74% |
| Hang Seng | 20,382.90 | -604.02 | -2.88% |
| S&P/ASX 200 | 4,758.39 | -102.99 | -2.12% |
Companies and a university are moving to offer cheaper and broader genetic testing for breast cancer risk to a growing group of women, following a U.S. Supreme Court ruling that ended Myriad Genetics Inc.’s monopoly over DNA that vastly raises odds for the disease.
Rate this Page